×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IVA – inventiva s.a. - american depository shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IVA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
04:00 pm
iva
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Medium
Report
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
11/15
04:00 pm
iva
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Low
Report
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
11/12
08:19 am
iva
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
10/30
04:00 pm
iva
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Medium
Report
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
10/21
08:30 am
iva
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Low
Report
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
10/15
01:32 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
10/14
01:45 pm
iva
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Medium
Report
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
10/14
02:35 am
iva
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
High
Report
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/20
04:33 pm
iva
Form 6-K Inventiva S.A. For: Nov 20
Medium
Report
Form 6-K Inventiva S.A. For: Nov 20
11/20
04:32 pm
iva
Form 6-K Inventiva S.A. For: Nov 20
Medium
Report
Form 6-K Inventiva S.A. For: Nov 20
11/15
04:32 pm
iva
Form 6-K Inventiva S.A. For: Nov 15
High
Report
Form 6-K Inventiva S.A. For: Nov 15
11/14
04:13 pm
iva
Form 6-K Inventiva S.A. For: Nov 14
Low
Report
Form 6-K Inventiva S.A. For: Nov 14
11/13
12:27 pm
iva
Form SCHEDULE 13G/A Inventiva S.A. Filed by: Yiheng Capital Management, L.P.
Low
Report
Form SCHEDULE 13G/A Inventiva S.A. Filed by: Yiheng Capital Management, L.P.
11/4
08:43 am
iva
Form 6-K Inventiva S.A. For: Nov 04
Low
Report
Form 6-K Inventiva S.A. For: Nov 04
10/30
04:57 pm
iva
Form 6-K Inventiva S.A. For: Oct 30
Medium
Report
Form 6-K Inventiva S.A. For: Oct 30
10/21
09:01 pm
iva
Form SC 13D/A Inventiva S.A. Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13D/A Inventiva S.A. Filed by: BIOTECHNOLOGY VALUE FUND L P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: